0
USD ▼
EUR USD GBP
+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Cardiovascular Therapeutics Market by Therapy Type, End User, Application, Delivery Mode - Global Forecast to 2030- Product Image
Cardiovascular Therapeutics Market by Therapy Type, End User, Application, Delivery Mode - Global Forecast to 2030- Product Image
Sale

Cardiovascular Therapeutics Market by Therapy Type, End User, Application, Delivery Mode - Global Forecast to 2030

  • PDF Icon

    Report

  • 188 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6010725
UP TO EUR$697USDGBP OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The cardiovascular therapeutics market is rapidly transforming in response to shifting demographics, emerging technologies, and evolving regulatory policies. Industry leaders face complex challenges and considerable opportunities as they adapt product offerings, supply chains, and business models in this dynamic landscape.

Market Snapshot: Cardiovascular Therapeutics Market Growth

The Cardiovascular Therapeutics Market grew from USD 50.71 billion in 2024 to USD 54.58 billion in 2025. It is expected to continue growing at a CAGR of 7.57%, reaching USD 78.57 billion by 2030. This expansion is driven by the rising global burden of cardiovascular disease and continued innovation in pharmacological therapies, medical devices, and digital care solutions. Senior decision-makers must navigate a landscape defined by regulatory adaptation, complex supply networks, and precision therapies addressing diverse patient needs.

Scope & Segmentation

This report delivers a granular view of the market, providing actionable insights by analyzing core segments, regional trends, and innovation-driven business models.

  • Therapy Types: Antiarrhythmics (including Class I–IV and further breakdown such as Amiodarone, Dofetilide, Sotalol), Anticoagulants (including Non-vitamin K Oral Anticoagulants such as Apixaban, Dabigatran, Rivaroxaban, and Vitamin K Antagonists), Antihypertensives (covering ACE Inhibitors, ARBs, Beta Blockers, Calcium Channel Blockers, Diuretics, Renin Inhibitors), and Lipid Lowering Agents (Ezetimibe, Fibrates, Niacin, PCSK9 Inhibitors, Statins).
  • End Users: Ambulatory Surgical Centers, Clinics, Home Care, Hospitals.
  • Applications: Arrhythmia, Coronary Artery Disease, Hyperlipidemia, Hypertension, Thromboembolic Disorders.
  • Delivery Modes: Implantable, Injectable, Oral, Transdermal therapies.
  • Regions: Americas (including major US states, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (including the United Kingdom, Germany, France, Russia, Italy, Spain, Gulf countries, South Africa, Nordics, and emerging African economies), and Asia-Pacific (with focus on China, India, Japan, Australia, South Korea, and Southeast Asian markets).
  • Leading Companies: Novartis AG, Pfizer Inc., Sanofi S.A., AstraZeneca PLC, Bayer AG, Merck & Co., Inc., Johnson & Johnson, Bristol-Myers Squibb Company, Amgen Inc., Boehringer Ingelheim GmbH.

Key Takeaways for Senior Decision-Makers

  • Continued advances in pharmacology, device engineering, and digital health are fueling an integrated therapeutic ecosystem, requiring alignment of R&D and commercialization strategies.
  • The shift toward precision medicine—supported by genomics and biomarker discovery—creates new pathways for stakeholder collaboration, reimbursement, and market access.
  • As digital health tools proliferate, patient engagement and real-world data generation will increasingly shape product development and clinical adoption.
  • Competitive dynamics are intensifying with the rise of generics and biosimilars, driving portfolio optimization, lifecycle management, and the need for robust IP strategies.
  • Regional differences in infrastructure, investment, and regulatory frameworks require tailored go-to-market strategies and adaptive pricing to capture value across mature and emerging markets.
  • Strong emphasis on collaboration is evident, as established players and emerging firms partner to accelerate innovation and streamline regulatory navigation.

Tariff Impact in the US Market

Recent tariff measures in the United States are placing upward pressure on production costs for pharmaceutical ingredients and finished medical devices. This has led manufacturers to reconsider sourcing and logistics strategies, with some prioritizing nearshoring and alternative suppliers. Larger corporations may absorb these impacts, but smaller manufacturers face greater financial and operational risks. Strategic alliances and optimized supply networks are critical for mitigating disruptions and maintaining market presence.

Methodology & Data Sources

This report adopts a comprehensive research methodology combining primary interviews with key opinion leaders, industry executives, and healthcare professionals, along with secondary analysis of clinical trials, regulatory filings, company disclosures, and market literature. Quantitative modeling assesses market drivers by segment, and peer review ensures credible, up-to-date findings.

Why This Report Matters

  • Empowers executives with a clear understanding of segment-specific opportunities, market drivers, and competitive positioning in the cardiovascular therapeutics market.
  • Enables anticipation of disruptive trends—such as tariff fluctuations, technological adoption, and regional policy shifts—to inform risk management and investment strategy.
  • Delivers actionable intelligence to support strategic planning, portfolio optimization, and regulatory preparedness—all tailored to the evolving demands of cardiovascular care.

Conclusion

The future of cardiovascular therapeutics will be shaped by the industry’s responsiveness to innovation, policy, and shifting patient needs. Leaders who integrate agility, collaboration, and evidence-driven decision-making into their strategies will be positioned for sustainable growth and impact.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing prevalence of cardiovascular diseases and aging population driving demand for advanced treatments
5.1.1.2. Technological advancements and innovation in cardiovascular therapeutics fostering market growth
5.1.1.3. Rising healthcare expenditure and supportive government policies boosting market expansion
5.1.1.4. Growing awareness about early diagnosis and treatment of cardiovascular conditions propelling market growth
5.1.2. Restraints
5.1.2.1. Limited awareness and understanding of cardiovascular diseases and their treatments among patients and primary care providers
5.1.2.2. Side effects and adverse reactions associated with cardiovascular therapeutics create hesitation among patients and healthcare providers to adopt new treatments
5.1.3. Opportunities
5.1.3.1. Expanding the reach of novel gene therapies for cardiovascular diseases through aggressive global marketing strategies
5.1.3.2. Leveraging AI-driven precision medicine to enhance treatment outcomes for complex cardiovascular conditions
5.1.3.3. Forming strategic collaborations with biotechnological firms to accelerate the development of pioneering cardiovascular drugs
5.1.4. Challenges
5.1.4.1. Complex clinical trial designs and stringent requirements leading to prolonged timeframes for cardiovascular drug approvals
5.1.4.2. Financial sustainability and profitability challenges impacting investments in cardiovascular research and development
5.2. Market Segmentation Analysis
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Cardiovascular Therapeutics Market, by Drug Class
6.1. Introduction
6.2. Antihypertensive Drugs
6.2.1. Beta Blockers
6.2.2. Calcium Channel Blockers
6.2.3. Renin-Angiotensin System Inhibitors
6.2.3.1. ACE Inhibitors
6.2.3.2. Angiotensin II Receptor Blockers
6.3. Antithrombotic Drugs
6.3.1. Anticoagulants
6.3.2. Antiplatelet Agents
6.3.3. Thrombolytics
6.4. Lipid-Lowering Drugs
6.4.1. Fibrates
6.4.2. Niacin
6.4.3. Statins
7. Cardiovascular Therapeutics Market, by Indication
7.1. Introduction
7.2. Angina Pectoris
7.3. Heart Failure
7.4. Hyperlipidemia
7.5. Hypertension
7.6. Myocardial Infarction
7.7. Stroke
8. Cardiovascular Therapeutics Market, by Patient Demographics
8.1. Introduction
8.2. Adult
8.3. Geriatric
8.4. Pediatric
9. Cardiovascular Therapeutics Market, by End-User
9.1. Introduction
9.2. Clinics
9.3. Emergency Services
9.4. Homecare Settings
9.5. Hospitals
10. Cardiovascular Therapeutics Market, by Route of Administration
10.1. Introduction
10.2. Oral
10.3. Parenteral
10.3.1. Intramuscular
10.3.2. Intravenous
10.4. Transdermal
11. Cardiovascular Therapeutics Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacies
11.3. Online Pharmacies
11.4. Retail Pharmacies
12. Americas Cardiovascular Therapeutics Market
12.1. Introduction
12.2. Argentina
12.3. Brazil
12.4. Canada
12.5. Mexico
12.6. United States
13. Asia-Pacific Cardiovascular Therapeutics Market
13.1. Introduction
13.2. Australia
13.3. China
13.4. India
13.5. Indonesia
13.6. Japan
13.7. Malaysia
13.8. Philippines
13.9. Singapore
13.10. South Korea
13.11. Taiwan
13.12. Thailand
13.13. Vietnam
14. Europe, Middle East & Africa Cardiovascular Therapeutics Market
14.1. Introduction
14.2. Denmark
14.3. Egypt
14.4. Finland
14.5. France
14.6. Germany
14.7. Israel
14.8. Italy
14.9. Netherlands
14.10. Nigeria
14.11. Norway
14.12. Poland
14.13. Qatar
14.14. Russia
14.15. Saudi Arabia
14.16. South Africa
14.17. Spain
14.18. Sweden
14.19. Switzerland
14.20. Turkey
14.21. United Arab Emirates
14.22. United Kingdom
15. Competitive Landscape
15.1. Market Share Analysis, 2023
15.2. FPNV Positioning Matrix, 2023
15.3. Competitive Scenario Analysis
15.4. Strategy Analysis & Recommendation
LIST OF FIGURES
FIGURE 1. CARDIOVASCULAR THERAPEUTICS MARKET RESEARCH PROCESS
FIGURE 2. CARDIOVASCULAR THERAPEUTICS MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
FIGURE 7. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
FIGURE 9. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2023 VS 2030 (%)
FIGURE 11. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
FIGURE 13. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
FIGURE 15. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
FIGURE 17. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. AMERICAS CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 19. AMERICAS CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. UNITED STATES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 21. UNITED STATES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 22. ASIA-PACIFIC CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 23. ASIA-PACIFIC CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 25. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 26. CARDIOVASCULAR THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 27. CARDIOVASCULAR THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023
LIST OF TABLES
TABLE 1. CARDIOVASCULAR THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. CARDIOVASCULAR THERAPEUTICS MARKET DYNAMICS
TABLE 7. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIHYPERTENSIVE DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY RENIN-ANGIOTENSIN SYSTEM INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ACE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANGIOTENSIN II RECEPTOR BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY RENIN-ANGIOTENSIN SYSTEM INHIBITORS, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIHYPERTENSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTITHROMBOTIC DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTICOAGULANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIPLATELET AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTITHROMBOTIC DRUGS, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY LIPID-LOWERING DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY FIBRATES, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY NIACIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY STATINS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY LIPID-LOWERING DRUGS, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANGINA PECTORIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY HEART FAILURE, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY HYPERLIPIDEMIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY HYPERTENSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY MYOCARDIAL INFARCTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY STROKE, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY EMERGENCY SERVICES, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIHYPERTENSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY RENIN-ANGIOTENSIN SYSTEM INHIBITORS, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTITHROMBOTIC DRUGS, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY LIPID-LOWERING DRUGS, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 65. ARGENTINA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 66. ARGENTINA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIHYPERTENSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 67. ARGENTINA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY RENIN-ANGIOTENSIN SYSTEM INHIBITORS, 2018-2030 (USD MILLION)
TABLE 68. ARGENTINA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTITHROMBOTIC DRUGS, 2018-2030 (USD MILLION)
TABLE 69. ARGENTINA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY LIPID-LOWERING DRUGS, 2018-2030 (USD MILLION)
TABLE 70. ARGENTINA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 71. ARGENTINA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 72. ARGENTINA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 73. ARGENTINA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 74. ARGENTINA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 75. ARGENTINA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 76. BRAZIL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 77. BRAZIL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIHYPERTENSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 78. BRAZIL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY RENIN-ANGIOTENSIN SYSTEM INHIBITORS, 2018-2030 (USD MILLION)
TABLE 79. BRAZIL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTITHROMBOTIC DRUGS, 2018-2030 (USD MILLION)
TABLE 80. BRAZIL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY LIPID-LOWERING DRUGS, 2018-2030 (USD MILLION)
TABLE 81. BRAZIL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 82. BRAZIL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 83. BRAZIL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 84. BRAZIL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 85. BRAZIL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 86. BRAZIL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 87. CANADA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 88. CANADA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIHYPERTENSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 89. CANADA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY RENIN-ANGIOTENSIN SYSTEM INHIBITORS, 2018-2030 (USD MILLION)
TABLE 90. CANADA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTITHROMBOTIC DRUGS, 2018-2030 (USD MILLION)
TABLE 91. CANADA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY LIPID-LOWERING DRUGS, 2018-2030 (USD MILLION)
TABLE 92. CANADA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 93. CANADA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 94. CANADA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 95. CANADA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 96. CANADA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 97. CANADA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 98. MEXICO CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 99. MEXICO CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIHYPERTENSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 100. MEXICO CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY RENIN-ANGIOTENSIN SYSTEM INHIBITORS, 2018-2030 (USD MILLION)
TABLE 101. MEXICO CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTITHROMBOTIC DRUGS, 2018-2030 (USD MILLION)
TABLE 102. MEXICO CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY LIPID-LOWERING DRUGS, 2018-2030 (USD MILLION)
TABLE 103. MEXICO CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 104. MEXICO CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 105. MEXICO CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 106. MEXICO CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 107. MEXICO CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 108. MEXICO CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 109. UNITED STATES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 110. UNITED STATES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIHYPERTENSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 111. UNITED STATES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY RENIN-ANGIOTENSIN SYSTEM INHIBITORS, 2018-2030 (USD MILLION)
TABLE 112. UNITED STATES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTITHROMBOTIC DRUGS, 2018-2030 (USD MILLION)
TABLE 113. UNITED STATES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY LIPID-LOWERING DRUGS, 2018-2030 (USD MILLION)
TABLE 114. UNITED STATES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 115. UNITED STATES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 116. UNITED STATES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 117. UNITED STATES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 118. UNITED STATES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 119. UNITED STATES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 120. UNITED STATES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 121. ASIA-PACIFIC CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 122. ASIA-PACIFIC CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIHYPERTENSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 123. ASIA-PACIFIC CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY RENIN-ANGIOTENSIN SYSTEM INHIBITORS, 2018-2030 (USD MILLION)
TABLE 124. ASIA-PACIFIC CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTITHROMBOTIC DRUGS, 2018-2030 (USD MILLION)
TABLE 125. ASIA-PACIFIC CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY LIPID-LOWERING DRUGS, 2018-2030 (USD MILLION)
TABLE 126. ASIA-PACIFIC CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 127. ASIA-PACIFIC CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 128. ASIA-PACIFIC CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 129. ASIA-PACIFIC CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 130. ASIA-PACIFIC CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 131. ASIA-PACIFIC CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 132. ASIA-PACIFIC CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 133. AUSTRALIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 134. AUSTRALIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIHYPERTENSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 135. AUSTRALIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY RENIN-ANGIOTENSIN SYSTEM INHIBITORS, 2018-2030 (USD MILLION)
TABLE 136. AUSTRALIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTITHROMBOTIC DRUGS, 2018-2030 (USD MILLION)
TABLE 137. AUSTRALIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY LIPID-LOWERING DRUGS, 2018-2030 (USD MILLION)
TABLE 138. AUSTRALIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 139. AUSTRALIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 140. AUSTRALIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 141. AUSTRALIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 142. AUSTRALIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 143. AUSTRALIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 144. CHINA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 145. CHINA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIHYPERTENSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 146. CHINA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY RENIN-ANGIOTENSIN SYSTEM INHIBITORS, 2018-2030 (USD MILLION)
TABLE 147. CHINA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTITHROMBOTIC DRUGS, 2018-2030 (USD MILLION)
TABLE 148. CHINA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY LIPID-LOWERING DRUGS, 2018-2030 (USD MILLION)
TABLE 149. CHINA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 150. CHINA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 151. CHINA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 152. CHINA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 153. CHINA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 154. CHINA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 155. INDIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 156. INDIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIHYPERTENSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 157. INDIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY RENIN-ANGIOTENSIN SYSTEM INHIBITORS, 2018-2030 (USD MILLION)
TABLE 158. INDIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTITHROMBOTIC DRUGS, 2018-2030 (USD MILLION)
TABLE 159. INDIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY LIPID-LOWERING DRUGS, 2018-2030 (USD MILLION)
TABLE 160. INDIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 161. INDIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 162. INDIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 163. INDIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 164. INDIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 165. INDIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 166. INDONESIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 167. INDONESIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIHYPERTENSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 168. INDONESIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY RENIN-ANGIOTENSIN SYSTEM INHIBITORS, 2018-2030 (USD MILLION)
TABLE 169. INDONESIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTITHROMBOTIC DRUGS, 2018-2030 (USD MILLION)
TABLE 170. INDONESIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY LIPID-LOWERING DRUGS, 2018-2030 (USD MILLION)
TABLE 171. INDONESIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 172. INDONESIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 173. INDONESIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 174. INDONESIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 175. INDONESIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 176. INDONESIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 177. JAPAN CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 178. JAPAN CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIHYPERTENSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 179. JAPAN CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY RENIN-ANGIOTENSIN SYSTEM INHIBITORS, 2018-2030 (USD MILLION)
TABLE 180. JAPAN CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTITHROMBOTIC DRUGS, 2018-2030 (USD MILLION)
TABLE 181. JAPAN CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY LIPID-LOWERING DRUGS, 2018-2030 (USD MILLION)
TABLE 182. JAPAN CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 183. JAPAN CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 184. JAPAN CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 185. JAPAN CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 186. JAPAN CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 187. JAPAN CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 188. MALAYSIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 189. MALAYSIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIHYPERTENSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 190. MALAYSIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY RENIN-ANGIOTENSIN SYSTEM INHIBITORS, 2018-2030 (USD MILLION)
TABLE 191. MALAYSIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTITHROMBOTIC DRUGS, 2018-2030 (USD MILLION)
TABLE 192. MALAYSIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY LIPID-LOWERING DRUGS, 2018-2030 (USD MILLION)
TABLE 193. MALAYSIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 194. MALAYSIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 195. MALAYSIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 196. MALAYSIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 197. MALAYSIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 198. MALAYSIA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 199. PHILIPPINES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 200. PHILIPPINES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIHYPERTENSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 201. PHILIPPINES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY RENIN-ANGIOTENSIN SYSTEM INHIBITORS, 2018-2030 (USD MILLION)
TABLE 202. PHILIPPINES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTITHROMBOTIC DRUGS, 2018-2030 (USD MILLION)
TABLE 203. PHILIPPINES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY LIPID-LOWERING DRUGS, 2018-2030 (USD MILLION)
TABLE 204. PHILIPPINES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 205. PHILIPPINES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 206. PHILIPPINES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 207. PHILIPPINES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 208. PHILIPPINES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 209. PHILIPPINES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 210. SINGAPORE CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 211. SINGAPORE CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIHYPERTENSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 212. SINGAPORE CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY RENIN-ANGIOTENSIN SYSTEM INHIBITORS, 2018-2030 (USD MILLION)
TABLE 213. SINGAPORE CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTITHROMBOTIC DRUGS, 2018-2030 (USD MILLION)
TABLE 214. SINGAPORE CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY LIPID-LOWERING DRUGS, 2018-2030 (USD MILLION)
TABLE 215. SINGAPORE CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 216. SINGAPORE CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 217. SINGAPORE CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 218. SINGAPORE CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 219. SINGAPORE CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 220. SINGAPORE CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 221. SOUTH KOREA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 222. SOUTH KOREA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIHYPERTENSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 223. SOUTH KOREA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY RENIN-ANGIOTENSIN SYSTEM INHIBITORS, 2018-2030 (USD MILLION)
TABLE 224. SOUTH KOREA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTITHROMBOTIC DRUGS, 2018-2030 (USD MILLION)
TABLE 225. SOUTH KOREA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY LIPID-LOWERING DRUGS, 2018-2030 (USD MILLION)
TABLE 226. SOUTH KOREA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 227. SOUTH KOREA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 228. SOUTH KOREA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 229. SOUTH KOREA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 230. SOUTH KOREA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 231. SOUTH KOREA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 232. TAIWAN CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 233. TAIWAN CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIHYPERTENSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 234. TAIWAN CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY RENIN-ANGIOTENSIN SYSTEM INHIBITORS, 2018-2030 (USD MILLION)
TABLE 235. TAIWAN CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTITHROMBOTIC DRUGS, 2018-2030 (USD MILLION)
TABLE 236. TAIWAN CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY LIPID-LOWERING DRUGS, 2018-2030 (USD MILLION)
TABLE 237. TAIWAN CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 238. TAIWAN CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 239. TAIWAN CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 240. TAIWAN CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 241. TAIWAN CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 242. TAIWAN CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 243. THAILAND CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 244. THAILAND CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIHYPERTENSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 245. THAILAND CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY RENIN-ANGIOTENSIN SYSTEM INHIBITORS, 2018-2030 (USD MILLION)
TABLE 246. THAILAND CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTITHROMBOTIC DRUGS, 2018-2030 (USD MILLION)
TABLE 247. THAILAND CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY LIPID-LOWERING DRUGS, 2018-2030 (USD MILLION)
TABLE 248. THAILAND CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 249. THAILAND CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 250. THAILAND CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 251. THAILAND CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 252. THAILAND CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 253. THAILAND CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 254. VIETNAM CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 255. VIETNAM CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIHYPERTENSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 256. VIETNAM CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY RENIN-ANGIOTENSIN SYSTEM INHIBITORS, 2018-2030 (USD MILLION)
TABLE 257. VIETNAM CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTITHROMBOTIC DRUGS, 2018-2030 (USD MILLION)
TABLE 258. VIETNAM CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY LIPID-LOWERING DRUGS, 2018-2030 (USD MILLION)
TABLE 259. VIETNAM CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 260. VIETNAM CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 261. VIETNAM CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 262. VIETNAM CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 263. VIETNAM CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 264. VIETNAM CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 265. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 266. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIHYPERTENSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 267. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY RENIN-ANGIOTENSIN SYSTEM INHIBITORS, 2018-2030 (USD MILLION)
TABLE 268. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTITHROMBOTIC DRUGS, 2018-2030 (USD MILLION)
TABLE 269. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY LIPID-LOWERING DRUGS, 2018-2030 (USD MILLION)
TABLE 270. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 271. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 272. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 273. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 274. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 275. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 276. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 277. DENMARK CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 278. DENMARK CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIHYPERTENSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 279. DENMARK CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY RENIN-ANGIOTENSIN SYSTEM INHIBITORS, 2018-2030 (USD MILLION)
TABLE 280. DENMARK CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTITHROMBOTIC DRUGS, 2018-2030 (USD MILLION)
TABLE 281. DENMARK CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY LIPID-LOWERING DRUGS, 2018-2030 (USD MILLION)
TABLE 282. DENMARK CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 283. DENMARK CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 284. DENMARK CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 285. DENMARK CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 286. DENMARK CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 287. DENMARK CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 288. EGYPT CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 289. EGYPT CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIHYPERTENSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 290. EGYPT CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY RENIN-ANGIOTENSIN SYSTEM INHIBITORS, 2018-2030 (USD MILLION)
TABLE 291. EGYPT CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTITHROMBOTIC DRUGS, 2018-2030 (USD MILLION)
TABLE 292. EGYPT CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY LIPID-LOWERING DRUGS, 2018-2030 (USD MILLION)
TABLE 293. EGYPT CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 294. EGYPT CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 295. EGYPT CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 296. EGYPT CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 297. EGYPT CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 298. EGYPT CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 299. FINLAND CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 300. FINLAND CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIHYPERTENSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 301. FINLAND CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY RENIN-ANGIOTENSIN SYSTEM INHIBITORS, 2018-2030 (USD MILLION)
TABLE 302. FINLAND CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTITHROMBOTIC DRUGS, 2018-2030 (USD MILLION)
TABLE 303. FINLAND CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY LIPID-LOWERING DRUGS, 2018-2030 (USD MIL

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Cardiovascular Therapeutics market report include:
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • AstraZeneca PLC
  • Bayer AG
  • Merck & Co., Inc.
  • Johnson & Johnson
  • Bristol-Myers Squibb Company
  • Amgen Inc.
  • Boehringer Ingelheim GmbH

Table Information

Report AttributeDetails
No. of Pages188
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 54.58 Billion
Forecasted Market Value ( USD ) by 2030 $ 78.57 Billion
Compound Annual Growth Rate7.5%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Cardiovascular Drugs Market by Dosage Form, Therapy Type, Distribution Channel, End User, Product Type - Global Forecast to 2030 - Product Image

Cardiovascular Drugs Market by Dosage Form, Therapy Type, Distribution Channel, End User, Product Type - Global Forecast to 2030

  • Report
  • 184 Pages
  • Global
From
EUR$3,545USDGBP
EUR$3,939USDGBP
Cardiovascular Drugs Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034 - Product Image

Cardiovascular Drugs Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034

  • Report
  • 140 Pages
  • Global
From
EUR$4,365USDGBP
EUR$4,850USDGBP
Cardiovascular Drugs - Global Strategic Business Report - Product Image

Cardiovascular Drugs - Global Strategic Business Report

  • Report
  • 413 Pages
  • Global
From
EUR$5,850USDGBP
Acute Coronary Syndrome Therapeutics Market by Drug Class, Indication, Route Of Administration, Distribution Channel, End User - Global Forecast to 2030 - Product Image

Acute Coronary Syndrome Therapeutics Market by Drug Class, Indication, Route Of Administration, Distribution Channel, End User - Global Forecast to 2030

  • Report
  • 186 Pages
  • Global
From
EUR$3,545USDGBP
EUR$3,939USDGBP
Acute Coronary Syndrome - Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

Acute Coronary Syndrome - Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 237 Pages
  • Global
From
EUR$7,950USDGBP

About the Cardiovascular Drugs Market

The Cardiovascular Drugs market is a segment of the pharmaceutical industry that focuses on the development and production of drugs used to treat cardiovascular diseases. These drugs are used to treat conditions such as hypertension, coronary artery disease, congestive heart failure, and arrhythmias. Cardiovascular drugs are also used to reduce the risk of stroke, heart attack, and other cardiovascular events. The market is composed of a variety of companies, ranging from large multinationals to small start-ups. Major players in the market include Pfizer, Merck, Novartis, Sanofi, and Bristol-Myers Squibb. These companies are involved in the research, development, and production of cardiovascular drugs. Additionally, there are a number of smaller companies that specialize in the production of generic cardiovascular drugs. These companies include Teva Pharmaceuticals, Mylan, and Sun Pharmaceuticals. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.
This website uses cookies to ensure you get the best experience. Learn more